Galectin Therapeutics
GALTGalectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer by targeting galectin proteins.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 4 weeks)Competitors
By market cap
Profile
Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer by targeting galectin proteins. The company utilizes proprietary manufacturing processes to create complex carbohydrate molecules from plant-based materials that inhibit galectin-3, a key mediator in disease pathogenesis. Its primary objective is to address life-threatening conditions with limited treatment options, specifically metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis.
A clinical-stage developer of first-in-class carbohydrate-based galectin inhibitors with a lead candidate in Phase 2b/3 trials for MASH cirrhosis.
Questions, answered.
- What is Galectin Therapeutics's market cap?
- Galectin Therapeutics (GALT) has a market capitalization of $302.9M and trades on NASDAQ.
- Who are Galectin Therapeutics's competitors?
- Galectin Therapeutics's key competitors include Madrigal Pharmaceuticals, Gilead Sciences, Altimmune, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Galectin Therapeutics partner with?
- Galectin Therapeutics's notable partners include Providence Portland Medical Center, SBH Sciences, Inc., Merck & Co., and others.
- What subsidiaries does Galectin Therapeutics have?
- Galectin Therapeutics's subsidiaries include Galectin Sciences LLC.
- Where is Galectin Therapeutics headquartered?
- Galectin Therapeutics is headquartered in United States of America and employs approximately 14 people. It has been publicly traded since 2002.